

# Levosimendan

## Catalog No: tcsc2501



### Available Sizes

**Size:** 100mg

**Size:** 500mg



### Specifications

**CAS No:**  
141505-33-1

**Formula:**  
 $C_{14}H_{12}N_6O$

**Pathway:**  
Autophagy

**Target:**  
Autophagy

**Purity / Grade:**  
>98%

**Solubility:**  
DMSO :  $\geq 50$  mg/mL (178.39 mM)

**Alternative Names:**  
OR1855;OR1259


**Observed Molecular Weight:**  
280.28

### Product Description

Levosimendan (OR1259) is a calcium sensitiser used in the management of acutely decompensated congestive heart failure.

***In Vitro:***

Levosimendan (OR1259) is a calcium sensitiser used in the management of acutely decompensated congestive heart failure. Levosimendan (OR1259) is an inodilator indicated for the short-term treatment of acutely decompensated severe chronic heart failure, and in situations where conventional therapy is not considered adequate. Levosimendan (OR1259) has shown preliminary positive effects in a range of conditions requiring inotropic support, including right ventricular failure, cardiogenic shock, septic shock, and Takotsubo cardiomyopathy<sup>[1]</sup>. The cardiovascular effects of Levosimendan (OR1259) are exerted via more than an isolated drug-receptor interaction, and involve favorable energetic and neurohormonal changes that are unique in comparison to other types of inodilators<sup>[2]</sup>. Levosimendan (OR1259) might reduce mortality in cardiac surgery and cardiology settings of adult patients<sup>[3]</sup>.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!